STOCKHOLM, November 3, 2014 – In accordance with the resolution passed by Elekta’s (EKTA-B.ST) Annual General Meeting on August 28, 2014, the Chairman of the Board has contacted the company’s four largest shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself, each of whom expressed an interest in participating in the Nomination Committee, and appointed one member (see below) to form Elekta’s Nomination Committee together with the Chairman of the Board. Nomination Committee members: · Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties’ holdings · Åsa Nisell, appointed by Swedbank Robur funds · Jens Barnevik, appointed by Didner & Gerge Funds · Anders Oscarsson, appointed by AMF and AMF Funds · Ossian Ekdahl, appointed by the First Swedish National Pension Fund The Nomination Committee will appoint one of its members as Chairman. The Nomination Committee is tasked ahead of the 2015 Annual General Meeting with preparing proposals pertaining to the number of Board members, Board fees, fees for committee work, the composition of the Board, election of the Chairman of the Board, election of the Chairman of the Annual General Meeting, auditors’ fees and election of auditors as well as guidelines for appointing the Nomination Committee. Shareholders wishing to submit proposals to Elekta’s Nomination Committee can do so by e-mail at valberedningen@elekta.com or by letter to: Elekta AB, Nomination Committee Box 7593 SE-103 93 Stockholm Sweden # # # For further information, please contact: Gert van Santen, Group Vice President Corporate Communications, Elekta AB Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com Time zone: CET: Central European Time Johan Andersson, Director, Investor Relations, Elekta AB Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com Time zone: CET: Central European Time The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 16:00 CET on November 3, 2014. About Elekta Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.
Elekta’s Nomination Committee for the 2015 Annual General
Top 10 Most Recent News Articles
Berlin Heals Puts Microcurrent Therapy to a Real Test
A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....
Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats
A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...
Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin
Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...
Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools
Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...
Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents
Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...
Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care
A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...
Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge
Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...
Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today
Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...
Continue Reading
Texas Restaurants Get a New Read on Customer Demand
Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...
Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows
Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...
Continue ReadingTop 5 Most Recently Viewed Articles
Investigation into GoHealth, Inc. Sparks Investor Concerns
GoHealth, Inc. Under Investigation for Alleged Securities Fraud Pomerantz LLP has initiated an investigation regarding potential claims involving investors of GoHealth, Inc. (NASDAQ: GOCO). This probe aims to determine whether the company and some of its executives have participated in misleading practices concerning their financial statements. The firm is reaching out to...
Continue Reading
Exploring the Features of the 2026 Toyota GR Corolla
Unleashing the Adventure with the 2026 Toyota GR Corolla Get ready for an adventurous experience with the all-new 2026 Toyota GR Corolla. Engineered to perfection, this vehicle is equipped with the innovative GR-FOUR All-Wheel Drive System, making it a formidable companion whether you're racing on the track or maneuvering through rugged terrains. The GR Corolla is...
Continue Reading
Tandem Diabetes Care Boosts Sales Guidance After Q3 Success
Tandem Diabetes Care Reports Impressive Q3 Financial Results Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading name in insulin delivery and diabetes management technology, has reported its financial accomplishments for the third quarter of 2024. Following an exceptional performance, the company has also increased its sales guidance for the upcoming fiscal year. Key...
Continue Reading
Green IT Services Growth: A Comprehensive Market Overview
Green IT Services Market: A Dynamic Overview The evolution of technology is more than just a trend; it represents a paradigm shift towards sustainability. As organizations embrace digital transformation, the focus on Green IT services has rapidly gained importance. The latest analyses indicate that the Green IT Services market, valued at USD 18.8 billion in recent years,...
Continue Reading
Duke Energy's Response to Hurricane Helene's Aftermath
Hurricane Helene Aftermath and Power Restoration Efforts Following the severe impact of Hurricane Helene, Duke Energy (NYSE: DUK) has made remarkable progress in restoring electrical services to over 2.16 million customers. Despite these extensive restoration efforts, around 334,000 customers are still without power, largely in Upstate South Carolina and the mountainous...
Continue Reading